Home
Plexxikon

Plexxikon Market Share Analysis for June 2026

engineering drugs for personalized medicines, plexxikon has earned a reputation as a leader in targeted drug discovery and translational, personalized medicine.

Health > Biotechnology and Pharmaceuticals

Domainplexxikon.com

Year Founded2001

Employees51 - 200

Annual Revenue$15M - $25M

Plexxikon

Plexxikon (including company regionals)

plexxikon.com

See more website traffic and engagement information

Plexxikon Revenue up to June 2026 is 15M - 25M

revenue generated by Plexxikon top domains

Plexxikon top domains revenue over 3 years

Revenue for Plexxikon top domains

plexxikon.com15M - 25M

See more with Sales Intelligence

Total visits to Plexxikon's top domains

Understand Plexxikon market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Plexxikon's top domains

Analyze Plexxikon engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Plexxikon's top domains

See how Plexxikon keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Plexxikon top competitors by domain

Top similar sites in June 2026, ranked by their affinity

dynavax.comCompany NameDynavax Technologies Corp.Employees201 - 500HQUnited States, California, EmeryvilleAnnual revenue$200M - $500MTotal visits6.1KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Plexxikon

These are the website technologies, by industry, used by Plexxikon top domains

Email Services (2)

Microsoft Exchange Online

Advertising (1)

Taxel

Audio Video Media (1)

Vimeo

Conversion & Analytics (1)

Google Analytics

More Technologies

4

See all

News & Signals from Plexxikon

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPlexxikon Inc. sold assets to Opna Bio SA on Mar 1st '22.OPN-2853 and OPN-7486 are part of the portfolio of small molecule oncology therapeutics Opna acquired from Plexxikon.

NewsDaiichi Sankyo Co., Ltd. acquired Plexxikon Inc. for $805M on Jan 1st '11.The cancer treatment had been at the center of Daiichi Sankyo's decision to buy Plexxikon for $805 million back in 2011 and, according to the complaint, it has generated more than $1.5 billion in worldwide sales for Daiichi Sankyo since.

NewsPlexxikon Inc. promoted Chao Zhang to chief executive officer on Jul 1st '21.Plexxikon, a member of the Daiichi Sankyo Group and a leader in structure-guided discovery and development of novel small molecule pharmaceuticals, today announced that Chao Zhang, PhD, has been promoted to chief executive officer from chief scientific officer.